GoodRx Appoints Kelly J. Kennedy to Board of Directors
December 22 2023 - 9:00AM
Business Wire
Former Chief Financial Officer of The Honest
Company brings over 25 years of experience across retail and
consumer brands
GoodRx (Nasdaq: GDRX), a leading resource for healthcare savings
and information, today announced the election of Kelly J. Kennedy
to its Board of Directors. Kennedy will serve as a member of the
Board’s audit committee and fill the seat left vacant by Jacqueline
Kosecoff earlier this year.
With over 25 years of experience serving in senior financial
roles for leading retail and consumer brands, Kennedy brings
extensive experience overseeing risk assessment management and
financial reporting at large public companies. Currently, Kennedy
serves as Chief Financial Officer for Willow Innovations, which
launched the world’s first wearable breast pump. Previously, she
served as Chief Financial Officer at The Honest Company, a
digital-first consumer goods company, and as Chief Financial
Officer of The Bartell Drug Company, a large family-owned pharmacy
chain, from September 2018 until its sale to Rite Aid in December
2020.
“Kelly has served at the helm of some of today’s highly notable
brands and we believe she will bring invaluable experience to
GoodRx as we continue to look for ways to strengthen and grow our
business,” said Trevor Bezdek, co-founder and Chairman of GoodRx.
“I look forward to working alongside her as we propel the company
forward in 2024 and beyond.”
In addition to her role on the GoodRx Board, Kennedy will
continue serving on the boards of Vital Farms, an ethical food
company; FirstFruit Farms, a premier grower, packer and shipper of
apples; Rad Power Bikes, an electric bike brand; and Skinny Mixes,
a producer of cocktail mixes and coffee syrups.
About GoodRx
GoodRx is a leading resource for healthcare savings and
information that makes healthcare affordable and convenient for all
Americans. We offer consumers free access to transparent and lower
prices for brand and generic medications, affordable and convenient
medical provider consultations via telehealth, and comprehensive
healthcare research and information. Since 2011, we have helped
consumers save over $65 billion and are one of the most downloaded
medical apps over the past decade.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding the benefits of, and anticipated contributions from,
Kelly J. Kennedy in her new directorship. These statements are
neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause our
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including,
but not limited to, the important factors discussed under the
caption “Risk Factors” in GoodRx’s Annual Report on Form 10-K for
the year ended December 31, 2022, as updated by GoodRx’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2023, and
our other filings with the SEC. These factors could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views
to change.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231222393864/en/
Investor Contact GoodRx Whitney Notaro
wnotaro@goodrx.com
Press Contact GoodRx Lauren Casparis
lcasparis@goodrx.com
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
From Apr 2024 to May 2024
GoodRx (NASDAQ:GDRX)
Historical Stock Chart
From May 2023 to May 2024